Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker REGN
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Jason Pitofsky Officer | REGN Regeneron Pharmaceuticals, Inc. | 3,883 | $3.8M | — | Nov 4, 2026 | Form 4 ↗ 2 days later · 4,062 shares | Form 144 ↗ |
| Nov 4, 2026 | Jason Pitofsky Officer | REGN Regeneron Pharmaceuticals, Inc. | 180 | $175.2K | — | Nov 4, 2026 | Form 4 ↗ 2 days later · 4,062 shares | Form 144 ↗ |
| Nov 3, 2026 | Huda Zoghbi Director | REGN Regeneron Pharmaceuticals, Inc. | 7,439 | $7.2M | — | Nov 3, 2026 | Form 4 ↗ 2 days later · 7,439 shares | Form 144 ↗ |
| Nov 2, 2026 | Joseph LaRosa Officer | REGN Regeneron Pharmaceuticals, Inc. | 4,466 | $4.3M | — | Nov 2, 2026 | Form 4 ↗ 2 days later · 4,466 shares | Form 144 ↗ |
| Nov 2, 2026 | Christine Poon Director | REGN Regeneron Pharmaceuticals, Inc. | 7,830 | $7.5M | — | Nov 2, 2026 | Form 4 ↗ 2 days later · 7,830 shares | Form 144 ↗ |
| Nov 2, 2026 | George L. Sing Director | REGN Regeneron Pharmaceuticals, Inc. | 21,129 | $20.4M | — | Nov 2, 2026 | Form 4 ↗ 2 days later · 21,129 shares | Form 144 ↗ |
| Oct 30, 2026 | Kathryn Guarini Director | REGN Regeneron Pharmaceuticals, Inc. | 400 | $360.0K | 10b5-1 | Oct 30, 2026 | Form 4 ↗ 4 days later · 400 shares | Form 144 ↗ |
| Oct 30, 2026 | Marion McCourt Officer | REGN Regeneron Pharmaceuticals, Inc. | 1,132 | $984.2K | 10b5-1 | Oct 30, 2026 | Form 4 ↗ 4 days later · 1,132 shares | Form 144 ↗ |
| Oct 30, 2026 | Michael S Brown Director | REGN Regeneron Pharmaceuticals, Inc. | 1,929 | $1.6M | 10b5-1 | Oct 30, 2026 | Form 4 ↗ 4 days later · 1,929 shares | Form 144 ↗ |
| Oct 14, 2026 | Andrew J. Murphy Officer | REGN Regeneron Pharmaceuticals, Inc. | 4,147 | $3.2M | 10b5-1 | Oct 14, 2026 | — | Form 144 ↗ |
| Sep 3, 2026 | Marion McCourt Officer | REGN Regeneron Pharmaceuticals, Inc. | 1,131 | $969.3K | 10b5-1 | Sep 3, 2026 | Form 4 ↗ same day · 2,346 shares | Form 144 ↗ |
| Sep 2, 2026 | Marion McCourt Officer | REGN Regeneron Pharmaceuticals, Inc. | 1,215 | $1.0M | 10b5-1 | Sep 2, 2026 | Form 4 ↗ 1 day later · 2,346 shares | Form 144 ↗ |
| Sep 2, 2026 | Kathryn Guarini Director | REGN Regeneron Pharmaceuticals, Inc. | 400 | $340.0K | 10b5-1 | Sep 2, 2026 | Form 4 ↗ 1 day later · 400 shares | Form 144 ↗ |
| Aug 10, 2026 | Huda Y. Zoghbi Director | REGN Regeneron Pharmaceuticals, Inc. | 800 | $640.0K | 10b5-1 | Aug 10, 2026 | Form 4 ↗ 2 days later · 800 shares | Form 144 ↗ |
| Aug 10, 2026 | Kathryn Guarini Board member | REGN Regeneron Pharmaceuticals, Inc. | 400 | $320.0K | 10b5-1 | Aug 10, 2026 | Form 4 ↗ 2 days later · 400 shares | Form 144 ↗ |
| Jul 2, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | 400 | $249.9K | 10b5-1 | Jul 2, 2026 | Form 4 ↗ 5 days later · 200 shares | Form 144 ↗ |
| Feb 19, 2026 | Huda Y. Zoghbi Director | REGN Regeneron Pharmaceuticals, Inc. | 1,638 | $1.3M | 10b5-1 | Feb 19, 2026 | Form 4 ↗ 4 days later · 1,638 shares | Form 144 ↗ |
| Feb 9, 2026 | Jason Pitofsky Officer | REGN Regeneron Pharmaceuticals, Inc. | 2,036 | $1.6M | 10b5-1 | Feb 9, 2026 | Form 4 ↗ 2 days later · 2,036 shares | Form 144 ↗ |
| Feb 9, 2026 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | 400 | $314.2K | 10b5-1 | Feb 9, 2026 | Form 4 ↗ 2 days later · 100 shares | Form 144 ↗ |
| Jan 7, 2026 | Bonnie L. Bassler Director | REGN Regeneron Pharmaceuticals, Inc. | 1,500 | $1.2M | 10b5-1 | Jan 7, 2026 | Form 4 ↗ 1 day later · 1,500 shares | Form 144 ↗ |
| Nov 20, 2025 | Bonnie L. Bassler Director | REGN Regeneron Pharmaceuticals, Inc. | 760 | $570.0K | 10b5-1 | Nov 20, 2025 | Form 4 ↗ 4 days later · 760 shares | Form 144 ↗ |
| Nov 7, 2025 | Jason Pitofsky Officer | REGN Regeneron Pharmaceuticals, Inc. | 431 | $280.6K | — | Nov 7, 2025 | Form 4 ↗ 3 days later · 431 shares | Form 144 ↗ |
| Oct 29, 2025 | Christine Poon Director | REGN Regeneron Pharmaceuticals, Inc. | 6,500 | $4.2M | — | Oct 29, 2025 | Form 4 ↗ 2 days later · 6,500 shares | Form 144 ↗ |
| Nov 1, 2024 | Marion E McCourt Officer | REGN Regeneron Pharmaceuticals, Inc. | 1,000 | $844.6K | 10b5-1 | Nov 1, 2024 | Form 4 ↗ 4 days later · 1,000 shares | Form 144 ↗ |
| Oct 1, 2024 | Marion E McCourt Officer | REGN Regeneron Pharmaceuticals, Inc. | 1,000 | $1.1M | 10b5-1 | Oct 1, 2024 | Form 4 ↗ 2 days later · 1,000 shares | Form 144 ↗ |
| Sep 3, 2024 | Marion E McCourt Officer | REGN Regeneron Pharmaceuticals, Inc. | 1,000 | $1.2M | 10b5-1 | Sep 3, 2024 | Form 4 ↗ 30 days later · 1,000 shares | Form 144 ↗ |
| Aug 28, 2024 | Christopher Fenimore Officer | REGN Regeneron Pharmaceuticals, Inc. | 5,680 | $6.8M | — | Aug 28, 2024 | — | Form 144 ↗ |
| Aug 15, 2024 | Christine Poon Director | REGN Regeneron Pharmaceuticals, Inc. | 10,838 | $12.5M | — | Aug 15, 2024 | — | Form 144 ↗ |
| Aug 15, 2024 | Bonnie L. Bassler Director | REGN Regeneron Pharmaceuticals, Inc. | 756 | $884.5K | 10b5-1 | Aug 15, 2024 | — | Form 144 ↗ |
| Aug 14, 2024 | Andrew J. Murphy Officer | REGN Regeneron Pharmaceuticals, Inc. | 6,363 | $7.3M | 10b5-1 | Aug 14, 2024 | — | Form 144 ↗ |
| Aug 8, 2024 | Neil Stahl Officer | REGN Regeneron Pharmaceuticals, Inc. | 5,197 | $5.6M | — | Aug 8, 2024 | — | Form 144 ↗ |
| Aug 7, 2024 | Jason Pitofsky Officer | REGN Regeneron Pharmaceuticals, Inc. | 487 | $521.0K | — | Aug 7, 2024 | — | Form 144 ↗ |
| Aug 2, 2024 | Bonnie L. Bassler Director | REGN Regeneron Pharmaceuticals, Inc. | 756 | $842.9K | 10b5-1 | Aug 2, 2024 | — | Form 144 ↗ |
| Aug 1, 2024 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | 300 | $323.8K | 10b5-1 | Aug 1, 2024 | Form 4 ↗ 63 days later · 100 shares | Form 144 ↗ |
| Aug 1, 2024 | Marion E McCourt Officer | REGN Regeneron Pharmaceuticals, Inc. | 1,137 | $1.2M | 10b5-1 | Aug 1, 2024 | Form 4 ↗ 63 days later · 1,000 shares | Form 144 ↗ |
| Jul 1, 2024 | Marion E McCourt Officer | REGN Regeneron Pharmaceuticals, Inc. | 1,137 | $1.2M | 10b5-1 | Jul 1, 2024 | — | Form 144 ↗ |
| Jun 24, 2024 | Bonnie L. Bassler Director | REGN Regeneron Pharmaceuticals, Inc. | 756 | $802.9K | 10b5-1 | Jun 24, 2024 | — | Form 144 ↗ |
| Jun 14, 2024 | Michael S Brown Director | REGN Regeneron Pharmaceuticals, Inc. | 1,535 | $1.6M | 10b5-1 | Jun 14, 2024 | — | Form 144 ↗ |
| Jun 12, 2024 | Leonard S. Schleifer Officer, Director | REGN Regeneron Pharmaceuticals, Inc. | 1,000 | $1.0M | 10b5-1 | Jun 12, 2024 | — | Form 144 ↗ |
| Jun 6, 2024 | Leonard S. Schleifer Officer | REGN Regeneron Pharmaceuticals, Inc. | 25,000 | $25.1M | 10b5-1 | Jun 6, 2024 | — | Form 144 ↗ |
| Jun 5, 2024 | Bonnie L. Bassler Director | REGN Regeneron Pharmaceuticals, Inc. | 827 | $836.1K | 10b5-1 | Jun 5, 2024 | — | Form 144 ↗ |
| Jun 3, 2024 | Marion E McCourt Officer | REGN Regeneron Pharmaceuticals, Inc. | 1,138 | $1.1M | 10b5-1 | Jun 3, 2024 | — | Form 144 ↗ |
| May 28, 2024 | Michael S Brown Director | REGN Regeneron Pharmaceuticals, Inc. | 1,172 | $1.2M | 10b5-1 | May 28, 2024 | — | Form 144 ↗ |
| May 21, 2024 | Joseph J. Larosa Officer | REGN Regeneron Pharmaceuticals, Inc. | 3,731 | $470.6K | 10b5-1 | May 21, 2024 | — | Form 144 ↗ |
| May 15, 2024 | George Yancopoulos Officer, Director | REGN Regeneron Pharmaceuticals, Inc. | 100,000 | $98.8M | 10b5-1 | May 15, 2024 | — | Form 144 ↗ |
| May 14, 2024 | Leonard S. Schleifer Officer, Director | REGN Regeneron Pharmaceuticals, Inc. | 58,771 | $57.6M | 10b5-1 | May 14, 2024 | — | Form 144 ↗ |
| May 1, 2024 | Arthur F. Ryan Director | REGN Regeneron Pharmaceuticals, Inc. | 300 | $266.7K | 10b5-1 | May 1, 2024 | — | Form 144 ↗ |
| May 1, 2024 | Marion E McCourt Officer | REGN Regeneron Pharmaceuticals, Inc. | 250 | $222.4K | 10b5-1 | May 1, 2024 | — | Form 144 ↗ |
| Apr 1, 2024 | Marion E McCourt Officer | REGN Regeneron Pharmaceuticals, Inc. | 250 | $241.2K | 10b5-1 | Apr 1, 2024 | — | Form 144 ↗ |
| Mar 14, 2024 | Andrew J. Murphy Officer | REGN Regeneron Pharmaceuticals, Inc. | 5,783 | $5.6M | 10b5-1 | Mar 14, 2024 | — | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 11:18 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances